Results 61 to 70 of about 313,286 (312)
Bridging the gap: Multi‐stakeholder perspectives of molecular diagnostics in oncology
Molecular Oncology, EarlyView.Although molecular diagnostics is transforming cancer care, implementing novel technologies remains challenging. This study identifies unmet needs and technology requirements through a two‐step stakeholder involvement. Liquid biopsies for monitoring applications and predictive biomarker testing emerge as key unmet needs. Technology requirements vary by
Jorine Arnouts +8 more
wiley +1 more source
Circulating tumor cells isolation: The “post-EpCAM era” [PDF]
, 2015 Circulating tumor cells (CTCs) represent a submicroscopic fraction detached from a primary tumor and in transit to a secondary site. The prognostic significance of CTCs in metastatic cancer patients was demonstrated for the first time more than ten years
Gradilone, Angela +2 more
core +1 more source
The role of circulating tumor DNA in patients with colon cancer
Тазовая хирургия и онкология, 2016 The term “liquid biopsy” describes the study of various tumor derivatives (circulating tumor DNA, circulating tumor cells, tumor RNA, tumor proteins) in the blood plasma. Results of liquid biopsy provide real-time information on the molecular pathologies
M. Yu. Fedyanin +2 more
doaj +1 more source
Advances in Laboratory Medicine, 2020 The term liquid biopsy is used in contraposition to the traditional “solid” tissue biopsy. In the oncology field it has opened a new plethora of clinical opportunities as tumor-derived material is shedded into the different biofluids from where it can be
Arechederra María +2 more
doaj +1 more source
Latest updates on cellular and molecular biomarkers of gliomas
Frontiers in Oncology, 2022 Gliomas are the most common central nervous system malignancies, compromising almost 80% of all brain tumors and is associated with significant mortality.
Maroun Bou Zerdan +6 more
doaj +1 more source
Molecular Oncology, EarlyView.A‐to‐I editing of miRNAs, particularly miR‐200b‐3p, contributes to HGSOC progression by enhancing cancer cell proliferation, migration and 3D growth. The edited form is linked to poorer patient survival and the identification of novel molecular targets.
Magdalena Niemira +14 more
wiley +1 more source
SPARC is a new myeloid-derived suppressor cell marker licensing suppressive activities [PDF]
, 2019 Myeloid-derived suppressor cells (MDSC) are well-known key negative regulators of the immune response during tumor growth, however scattered is the knowledge of their capacity to influence and adapt to the different tumor microenvironments and of the ...
Botti L. +12 more
core +3 more sources
Human plasmacytoid dendritic cells and cutaneous melanoma [PDF]
, 2020 The prognosis of metastatic melanoma (MM) patients has remained poor for a long time. However, the recent introduction of effective target therapies (BRAF and MEK inhibitors for BRAFV600-mutated MM) and immunotherapies (anti-CTLA-4 and anti-PD-1) has ...
Bugatti, Mattia +4 more
core +2 more sources
Molecular Oncology, EarlyView.This study indicates that Merkel cell carcinoma (MCC) does not originate from Merkel cells, and identifies gene, protein & cellular expression of immune‐linked and neuroendocrine markers in primary and metastatic Merkel cell carcinoma (MCC) tumor samples, linked to Merkel cell polyomavirus (MCPyV) status, with enrichment of B‐cell and other immune cell
Richie Jeremian +10 more
wiley +1 more source
Nucleosomes in pancreatic cancer patients during radiochemotherapy [PDF]
, 2005 Nucleosomes appear spontaneously in elevated concentrations in the serum of patients with malignant diseases as well as during chemo- and radiotherapy. We analyzed whether their kinetics show typical characteristics during radiochemotherapy and enable an
Amoura Z +19 more
core +1 more source